flurbiprofen has been researched along with Kidney Diseases in 7 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flurbiprofen, however, was faster-acting and superior to dipirone + hyoscine in the overall evaluation of good and excellent therapeutic response rates." | 2.68 | [Flubiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic]. ( Arrizabalaga Moreno, M; Camp Herrero, J; del Nogal Saez, F; Domínguez Granados, R; Extramiana Cameno, J; Gimeno Albo, F; Milla Santos, J; Mora Durban, MJ; Moreno Carretero, E; Paniagua Andrés, P, 1995) |
| " Renal function was assessed in eight patients with chronic renal insufficiency following the administration of flurbiprofen 50 mg as a single dose and after chronic administration of 50 mg four times daily for 8 and 27 days." | 2.67 | Effects of flurbiprofen on renal function in patients with moderate renal insufficiency. ( Brater, DC; Greene, PK; Hall, SD; Manatunga, AK; Murray, MD, 1992) |
| " CDDP-induced nephrotoxicity (CIN) is one of the most severe adverse events associated with the use of CDDP." | 1.56 | Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. ( Furugen, A; Iseki, K; Kobayashi, M; Narumi, K; Okamoto, K; Saito, Y, 2020) |
| "Flurbiprofen-treated rats showed severe gastrointestinal ulcerations (bleeding in 3/8 rats) and nefrotoxicity, which was not observed in nitroflurbiprofen-treated cirrhotic rats." | 1.34 | Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. ( Fevery, J; Laleman, W; Nevens, F; Van der Elst, I; Van Landeghem, L; Zeegers, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Okamoto, K | 1 |
| Saito, Y | 1 |
| Narumi, K | 1 |
| Furugen, A | 1 |
| Iseki, K | 1 |
| Kobayashi, M | 1 |
| Gonçalves, AR | 1 |
| Fujihara, CK | 1 |
| Mattar, AL | 1 |
| Malheiros, DM | 1 |
| Noronha, Ide L | 1 |
| de Nucci, G | 1 |
| Zatz, R | 1 |
| Laleman, W | 1 |
| Van Landeghem, L | 1 |
| Van der Elst, I | 1 |
| Zeegers, M | 1 |
| Fevery, J | 1 |
| Nevens, F | 1 |
| Blouin, R | 1 |
| Chaudhary, I | 1 |
| Nishihara, K | 1 |
| Cox, S | 1 |
| Mora Durban, MJ | 1 |
| Extramiana Cameno, J | 1 |
| Arrizabalaga Moreno, M | 1 |
| Paniagua Andrés, P | 1 |
| Camp Herrero, J | 1 |
| Milla Santos, J | 1 |
| del Nogal Saez, F | 1 |
| Gimeno Albo, F | 1 |
| Moreno Carretero, E | 1 |
| Domínguez Granados, R | 1 |
| Julián Mora, M | 1 |
| Extramiana, J | 1 |
| Navarro, FJ | 1 |
| Arrizabalaga, M | 1 |
| Mañas, A | 1 |
| González, P | 1 |
| Pérez, MJ | 1 |
| Paniagua, P | 1 |
| Murray, MD | 1 |
| Greene, PK | 1 |
| Brater, DC | 1 |
| Manatunga, AK | 1 |
| Hall, SD | 1 |
3 trials available for flurbiprofen and Kidney Diseases
| Article | Year |
|---|---|
[Flubiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butylscopola | 1995 |
[Flurbiprofen: therapeutic alternative in nephritic colic].
Topics: Adult; Aged; Colic; Dipyrone; Double-Blind Method; Drug Therapy, Combination; Female; Flurbiprofen; | 1992 |
Effects of flurbiprofen on renal function in patients with moderate renal insufficiency.
Topics: Aged; Blood Pressure; Body Weight; Female; Flurbiprofen; Hemodynamics; Humans; Indomethacin; Kidney; | 1992 |
4 other studies available for flurbiprofen and Kidney Diseases
| Article | Year |
|---|---|
Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Celecoxib; Cell Line; Cisplatin; Cytopr | 2020 |
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cyclooxyg | 2004 |
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Topics: Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Endoth | 2007 |
The effects of liver and renal disease on stereoselective serum binding of flurbiprofen.
Topics: Adult; Aged; Blood Proteins; Flurbiprofen; Humans; Kidney Diseases; Liver Diseases; Male; Middle Age | 1993 |